{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T05:42:05Z","timestamp":1789191725818,"version":"build-2803163510"},"reference-count":95,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2011,12,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Aggressive B-cell lymphomas are clinically and pathologically diverse and reflect multiple pathways of transformation. The 2008 World Health Organization (WHO) classification reflects this complexity with the addition of several new entities and variants. Whereas MYC translocations have long been associated with Burkitt lymphoma (BL), deregulation of MYC has been shown to occur in other aggressive B-cell lymphomas, most often as a secondary event. Lymphomas with translocations of both MYC and BCL2 are highly aggressive tumors, with a high failure rate with most treatment protocols. These \u201cdouble-hit\u201d lymphomas are now separately delineated in the WHO classification as B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma (DLBCL) and BL. A MYC translocation is also found uncommonly in DLBCL, but the clinical consequences of this in the absence of a double hit are not yet fully delineated. Most recently, MYC translocations have been identified as a common secondary event in plasma cell neoplasms, seen in approximately 50% of plasmablastic lymphoma. Another area that has received recent attention is the spectrum of EBV-driven B-cell proliferations in patients without iatrogenic or congenital immunosuppression; most of these occur in patients of advanced age and include the EBV-positive large B-cell lymphomas of the elderly.<\/jats:p>","DOI":"10.1182\/asheducation-2011.1.506","type":"journal-article","created":{"date-parts":[[2011,12,7]],"date-time":"2011-12-07T20:33:13Z","timestamp":1323289993000},"page":"506-514","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":80,"title":["Aggressive B-Cell Lymphomas: A Review of New and Old Entities in the WHO Classification"],"prefix":"10.1182","volume":"2011","author":[{"given":"Elaine S.","family":"Jaffe","sequence":"first","affiliation":[{"name":"Hematopathology Section, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Pittaluga","sequence":"additional","affiliation":[{"name":"Hematopathology Section, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"19","key":"2019111717365866500_B1","doi-asserted-by":"crossref","first-page":"5019","DOI":"10.1182\/blood-2011-01-293050","article-title":"The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications","volume":"117","author":"Campo","year":"2011","journal-title":"Blood"},{"issue":"7277","key":"2019111717365866500_B2","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nature08638","article-title":"Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma","volume":"463","author":"Davis","year":"2010","journal-title":"Nature"},{"issue":"7332","key":"2019111717365866500_B3","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/nature09671","article-title":"Oncogenically active MYD88 mutations in human lymphoma","volume":"470","author":"Ngo","year":"2011","journal-title":"Nature"},{"issue":"3","key":"2019111717365866500_B4","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.ccr.2007.08.011","article-title":"A signaling pathway mediating downregulation of BCL6 in germinal center B cells is blocked by BCL6 gene alterations in B cell lymphoma","volume":"12","author":"Saito","year":"2007","journal-title":"Cancer Cell"},{"key":"2019111717365866500_B5","first-page":"106","article-title":"MYC+ aggressive-B-cell lymphomas: novel therapy of untreated Burkitt lymphoma (BL) and MYC+ diffuse large B-cell lymphoma (DLBCL) with DA-EPOCH-R [Abstract]","volume":"22","author":"Dunleavy","year":"2011","journal-title":"Ann Oncol"},{"issue":"17","key":"2019111717365866500_B6","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1182\/blood-2009-05-220095","article-title":"MYC gene re-arrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy","volume":"114","author":"Savage","year":"2009","journal-title":"Blood"},{"issue":"1","key":"2019111717365866500_B7","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0002-9440(10)63284-1","article-title":"BCL2 Translocation defines a unique tumor subset within the germinal center B-cell-like diffuse large B-cell lymphoma","volume":"165","author":"Iqbal","year":"2004","journal-title":"Am J Pathol"},{"issue":"25","key":"2019111717365866500_B8","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1056\/NEJMoa012914","article-title":"The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma","volume":"346","author":"Rosenwald","year":"2002","journal-title":"N Engl J Med"},{"issue":"5870","key":"2019111717365866500_B9","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1126\/science.1153629","article-title":"Oncogenic CARD11 mutations in human diffuse large B cell lymphoma","volume":"319","author":"Lenz","year":"2008","journal-title":"Science"},{"issue":"9","key":"2019111717365866500_B10","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1182\/blood-2010-03-272567","article-title":"MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-{kappa}B-dependent lymphoma","volume":"116","author":"Milhollen","year":"2010","journal-title":"Blood"},{"issue":"22","key":"2019111717365866500_B11","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1056\/NEJMoa0802885","article-title":"Stromal gene signatures in large-B-cell lymphomas","volume":"359","author":"Lenz","year":"2008","journal-title":"N Engl J Med"},{"issue":"1","key":"2019111717365866500_B12","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","article-title":"Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray","volume":"103","author":"Hans","year":"2004","journal-title":"Blood"},{"issue":"26","key":"2019111717365866500_B13","doi-asserted-by":"crossref","first-page":"7070","DOI":"10.1182\/blood-2011-04-345256","article-title":"Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium","volume":"117","author":"Salles","year":"2011","journal-title":"Blood"},{"issue":"2","key":"2019111717365866500_B14","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1200\/JCO.2010.30.0368","article-title":"Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab","volume":"29","author":"Meyer","year":"2011","journal-title":"J Clin Oncol"},{"issue":"17","key":"2019111717365866500_B15","doi-asserted-by":"crossref","first-page":"5494","DOI":"10.1158\/1078-0432.CCR-09-0113","article-title":"A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy","volume":"15","author":"Choi","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"8","key":"2019111717365866500_B16","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1038\/modpathol.2009.73","article-title":"Prognostic impact of activated B-cell focused classification in diffuse large B-cell lymphoma patients treated with R-CHOP","volume":"22","author":"Nyman","year":"2009","journal-title":"Mod Pathol"},{"issue":"18","key":"2019111717365866500_B17","doi-asserted-by":"crossref","first-page":"4836","DOI":"10.1182\/blood-2010-12-322362","article-title":"Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy","volume":"117","author":"Guti\u00e9rrez-Garc\u00eda","year":"2011","journal-title":"Blood"},{"issue":"5","key":"2019111717365866500_B18","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1080\/10428190500051844","article-title":"Validation of tissue microarray immunohistochemistry staining and interpretation in diffuse large B-cell lymphoma","volume":"46","author":"Zu","year":"2005","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"2019111717365866500_B19","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1136\/jcp.2008.057257","article-title":"Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications (a study from the Lunenburg Lymphoma Biomarker Consortium)","volume":"62","author":"de Jong","year":"2009","journal-title":"J Clin Pathol"},{"issue":"7","key":"2019111717365866500_B20","first-page":"2291","article-title":"Subclassification of diffuse large B-cell lymphomas according to the Kiel classification: distinction of centroblastic and immunoblastic lymphomas is a significant prognostic risk factor","volume":"89","author":"Engelhard","year":"1997","journal-title":"Blood"},{"issue":"23","key":"2019111717365866500_B21","doi-asserted-by":"crossref","first-page":"4916","DOI":"10.1182\/blood-2010-03-276766","article-title":"Immunoblastic morphology but not the immunohistochemical GCB\/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL","volume":"116","author":"Ott","year":"2010","journal-title":"Blood"},{"issue":"8","key":"2019111717365866500_B22","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.3324\/haematol.12810","article-title":"De novo CD5+ diffuse large B-cell lymphoma: results of a detailed clinicopathological review in 120 patients","volume":"93","author":"Yamaguchi","year":"2008","journal-title":"Haematologica"},{"issue":"6","key":"2019111717365866500_B23","doi-asserted-by":"crossref","first-page":"3200","DOI":"10.1182\/blood-2007-10-119099","article-title":"Pathway analysis of primary central nervous system lymphoma","volume":"111","author":"Tun","year":"2008","journal-title":"Blood"},{"issue":"4","key":"2019111717365866500_B24","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1182\/blood-2010-07-297861","article-title":"Genomic profiling combined with gene expression profiling in primary central nervous system lymphoma","volume":"117","author":"Sung","year":"2011","journal-title":"Blood"},{"issue":"1","key":"2019111717365866500_B25","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1182\/blood-2008-04-152835","article-title":"Differential gene expression in central nervous system lymphoma","volume":"113","author":"Rubenstein","year":"2009","journal-title":"Blood"},{"issue":"12","key":"2019111717365866500_B26","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1038\/modpathol.3800691","article-title":"Primary testicular diffuse large B-cell lymphoma belongs to the nongerminal center B-cell-like subgroup: A study of 18 cases","volume":"19","author":"Al-Abbadi","year":"2006","journal-title":"Mod Pathol"},{"issue":"2","key":"2019111717365866500_B27","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/path.2399","article-title":"Genomic alterations and gene expression in primary diffuse large B-cell lymphomas of immune-privileged sites: the importance of apoptosis and immunomodulatory pathways","volume":"216","author":"Booman","year":"2008","journal-title":"J Pathol"},{"issue":"10","key":"2019111717365866500_B28","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.1182\/blood-2004-09-3502","article-title":"WHO-EORTC classification for cutaneous lymphomas","volume":"105","author":"Willemze","year":"2005","journal-title":"Blood"},{"issue":"9","key":"2019111717365866500_B29","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.1182\/blood-2004-04-1594","article-title":"Distinct types of primary cutaneous large B-cell lymphoma identified by gene expression profiling","volume":"105","author":"Hoefnagel","year":"2005","journal-title":"Blood"},{"issue":"10","key":"2019111717365866500_B30","doi-asserted-by":"crossref","first-page":"3662","DOI":"10.1182\/blood-2003-08-2726","article-title":"Bcl-2 protein expression is the strongest independent prognostic factor of survival in primary cutaneous large B-cell lymphomas","volume":"103","author":"Grange","year":"2004","journal-title":"Blood"},{"issue":"21","key":"2019111717365866500_B31","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1200\/JCO.2006.08.2313","article-title":"Definition, diagnosis, and management of intravascular large B-cell lymphoma: proposals and perspectives from an international consensus meeting","volume":"25","author":"Ponzoni","year":"2007","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019111717365866500_B32","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1182\/blood-2006-01-021253","article-title":"Intravascular large B-cell lymphoma (IVLBCL): a clinicopathologic study of 96 cases with special reference to the immunophenotypic heterogeneity of CD5","volume":"109","author":"Murase","year":"2007","journal-title":"Blood"},{"issue":"1","key":"2019111717365866500_B33","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1046\/j.1365-2559.2002.01291.x","article-title":"Histiocyte-rich, T-cell-rich B-cell lymphoma: a distinct diffuse large B-cell lymphoma subtype showing characteristic morphologic and immunophenotypic features","volume":"40","author":"Achten","year":"2002","journal-title":"Histopathology"},{"issue":"5","key":"2019111717365866500_B34","first-page":"1269","article-title":"T-cell\/histiocyte\u2013rich large B-cell lymphoma: a distinct clinicopathologic entity","volume":"20","author":"Achten","year":"2002","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019111717365866500_B35","doi-asserted-by":"crossref","first-page":"440","DOI":"10.3324\/haematol.2009.009647","article-title":"T-cell\/histiocyte-rich large B-cell lymphoma shows transcriptional features suggestive of a tolerogenic host immune response","volume":"95","author":"Van Loo","year":"2010","journal-title":"Haematologica"},{"issue":"3","key":"2019111717365866500_B36","doi-asserted-by":"crossref","first-page":"352","DOI":"10.3324\/haematol.2009.016931","article-title":"T-cell\/histiocyte-rich large B-cell lymphoma","volume":"95","author":"Pittaluga","year":"2010","journal-title":"Haematologica"},{"issue":"11","key":"2019111717365866500_B37","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1097\/00000478-200211000-00008","article-title":"T-cell\/histiocyte-rich large B-cell lymphoma: a heterogeneous entity with derivation from germinal center B cells","volume":"26","author":"Lim","year":"2002","journal-title":"Am J Surg Pathol"},{"issue":"17","key":"2019111717365866500_B38","doi-asserted-by":"crossref","first-page":"5124","DOI":"10.1158\/1078-0432.CCR-06-2823","article-title":"Age-related EBV-associated B-cell lymphoproliferative disorders constitute a distinct clinicopathologic group: a study of 96 patients","volume":"13","author":"Oyama","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"12","key":"2019111717365866500_B39","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1182\/blood-2008-06-164806","article-title":"Age-related Epstein-Barr virus (EBV)-associated B-cell lymphoproliferative disorders: comparison with EBV-positive classic Hodgkin lymphoma in elderly patients","volume":"113","author":"Asano","year":"2009","journal-title":"Blood"},{"issue":"18","key":"2019111717365866500_B40","doi-asserted-by":"crossref","first-page":"4726","DOI":"10.1182\/blood-2010-12-323238","article-title":"Age-related EBV-associated lymphoproliferative disorder: a spectrum of reactive lymphoid hyperplasia and lymphoma: the Western experience","volume":"117","author":"Dojcinov","year":"2011","journal-title":"Blood"},{"issue":"3","key":"2019111717365866500_B41","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/PAS.0b013e3181cf8622","article-title":"EBV positive mucocutaneous ulcer\u2013a study of 26 cases associated with various sources of immunosuppression","volume":"34","author":"Dojcinov","year":"2010","journal-title":"Am J Surg Pathol"},{"issue":"5","key":"2019111717365866500_B42","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1093\/ajcp\/93.5.698","article-title":"Acute infectious mononucleosis. CD30 (Ki-1) antigen expression and histologic correlations","volume":"93","author":"Abbondanzo","year":"1990","journal-title":"Am J Clin Pathol"},{"issue":"10","key":"2019111717365866500_B43","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1097\/00000478-199610000-00015","article-title":"Hodgkin's disease and lymphoproliferations resembling Hodgkin's disease in patients receiving long-term low-dose methotrexate therapy","volume":"20","author":"Kamel","year":"1996","journal-title":"Am J Surg Pathol"},{"issue":"6","key":"2019111717365866500_B44","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1097\/01.pap.0000194627.50878.02","article-title":"Pyothorax-associated lymphoma: a lymphoma developing in chronic inflammation","volume":"12","author":"Aozasa","year":"2005","journal-title":"Adv Anat Pathol"},{"issue":"4","key":"2019111717365866500_B45","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/modpathol.2009.168","article-title":"Diffuse large B-cell lymphoma associated with chronic inflammation as an incidental finding and new clinical scenarios","volume":"23","author":"Loong","year":"2010","journal-title":"Mod Pathol"},{"issue":"6","key":"2019111717365866500_B46","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1097\/00000478-200206000-00005","article-title":"Pyothorax-associated lymphoma: a peculiar clinicopathologic entity derived from B cells at late stage of differentiation and with occasional aberrant dual B- and T-cell phenotype","volume":"26","author":"Petitjean","year":"2002","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"2019111717365866500_B47","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S1470-2045(02)00714-3","article-title":"Mediastinal (thymic) large B-cell lymphoma: where do we stand?","volume":"3","author":"Barth","year":"2002","journal-title":"Lancet Oncol"},{"issue":"4","key":"2019111717365866500_B48","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1182\/blood-2004-12-4901","article-title":"NFkappaB activity, function, and target-gene signatures in primary mediastinal large B-cell lymphoma and diffuse large B-cell lymphoma subtypes","volume":"106","author":"Feuerhake","year":"2005","journal-title":"Blood"},{"issue":"17","key":"2019111717365866500_B49","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1182\/blood-2010-05-282780","article-title":"Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma","volume":"116","author":"Green","year":"2010","journal-title":"Blood"},{"issue":"6","key":"2019111717365866500_B50","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.ccr.2010.11.013","article-title":"Cooperative epigenetic modulation by cancer amplicon genes","volume":"18","author":"Rui","year":"2010","journal-title":"Cancer Cell"},{"issue":"2","key":"2019111717365866500_B51","doi-asserted-by":"crossref","first-page":"262","DOI":"10.3324\/haematol.2010.030809","article-title":"Clinical, pathological and genetic features of primary mediastinal large B-cell lymphomas and mediastinal gray zone lymphomas in children","volume":"96","author":"Oschlies","year":"2011","journal-title":"Haematologica"},{"issue":"11","key":"2019111717365866500_B52","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1097\/01.pas.0000180856.74572.73","article-title":"Mediastinal gray zone lymphoma: the missing link between classic Hodgkin's lymphoma and mediastinal large B-cell lymphoma","volume":"29","author":"Traverse-Glehen","year":"2005","journal-title":"Am J Surg Pathol"},{"issue":"6","key":"2019111717365866500_B53","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1084\/jem.20031074","article-title":"Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma","volume":"198","author":"Rosenwald","year":"2003","journal-title":"J Exp Med"},{"issue":"12","key":"2019111717365866500_B54","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.1182\/blood-2003-06-1841","article-title":"The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma","volume":"102","author":"Savage","year":"2003","journal-title":"Blood"},{"issue":"5","key":"2019111717365866500_B55","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1182\/blood.V89.5.1483","article-title":"A new subtype of large B-cell lymphoma expressing the ALK kinase and lacking the 2; 5 translocation","volume":"89","author":"Delsol","year":"1997","journal-title":"Blood"},{"issue":"10","key":"2019111717365866500_B56","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1038\/sj.leu.2403921","article-title":"ALK-positive diffuse large B-cell lymphoma with ALK-Clathrin fusion belongs to the spectrum of pediatric lymphomas","volume":"19","author":"Gesk","year":"2005","journal-title":"Leukemia"},{"issue":"25","key":"2019111717365866500_B57","doi-asserted-by":"crossref","first-page":"4211","DOI":"10.1200\/JCO.2008.21.5020","article-title":"Anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma: a rare clinicopathologic entity with poor prognosis","volume":"27","author":"Laurent","year":"2009","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111717365866500_B58","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1182\/blood.V89.4.1413","article-title":"Plasmablastic lymphomas of the oral cavity: a new entity associated with the human immunodeficiency virus infection","volume":"89","author":"Delecluse","year":"1997","journal-title":"Blood"},{"issue":"6","key":"2019111717365866500_B59","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1097\/01.pas.0000126781.87158.e3","article-title":"Diffuse large B-cell lymphomas with plasmablastic differentiation represent a heterogeneous group of disease entities","volume":"28","author":"Colomo","year":"2004","journal-title":"Am J Surg Pathol"},{"issue":"7","key":"2019111717365866500_B60","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/modpathol.2010.72","article-title":"Plasmablastic lymphoma with MYC translocation: evidence for a common pathway in the generation of plasmablastic features","volume":"23","author":"Taddesse-Heath","year":"2010","journal-title":"Mod Pathol"},{"issue":"11","key":"2019111717365866500_B61","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1097\/PAS.0b013e3181f3e29f","article-title":"IG\/MYC rearrangements are the main cytogenetic alteration in plasmablastic lymphomas","volume":"34","author":"Valera","year":"2010","journal-title":"Am J Surg Pathol"},{"issue":"7","key":"2019111717365866500_B62","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/gcc.20563","article-title":"Secondary genomic rearrangements involving immunoglobulin or MYC loci show similar prevalences in hyperdiploid and nonhyperdiploid myeloma tumors","volume":"47","author":"Gabrea","year":"2008","journal-title":"Genes Chromosomes Cancer"},{"issue":"18","key":"2019111717365866500_B63","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1056\/NEJM199505043321802","article-title":"Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas","volume":"332","author":"Cesarman","year":"1995","journal-title":"N Engl J Med"},{"issue":"2","key":"2019111717365866500_B64","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1002\/(SICI)1096-9896(199910)189:2<288::AID-PATH419>3.0.CO;2-F","article-title":"Expression of potentially oncogenic HHV-8 genes in an EBV-negative primary effusion lymphoma occurring in an HIV-seronegative patient","volume":"189","author":"Cobo","year":"1999","journal-title":"J Pathol"},{"issue":"12","key":"2019111717365866500_B65","first-page":"1637","article-title":"Expression of human herpesvirus-8 oncogene and cytokine homologues in an HIV-seronegative patient with multicentric Castleman's disease and primary effusion lymphoma","volume":"78","author":"Teruya-Feldstein","year":"1998","journal-title":"Lab Invest"},{"issue":"11","key":"2019111717365866500_B66","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1097\/01.pas.0000138177.10829.5c","article-title":"KSHV-positive solid lymphomas represent an extra-cavitary variant of primary effusion lymphoma","volume":"28","author":"Chadburn","year":"2004","journal-title":"Am J Surg Pathol"},{"issue":"8","key":"2019111717365866500_B67","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1097\/00000478-199908000-00023","article-title":"A biophenotypic human herpesvirus 8-associated primary bowel lymphoma","volume":"23","author":"Beaty","year":"1999","journal-title":"Am J Surg Pathol"},{"issue":"10","key":"2019111717365866500_B68","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.4161\/cbt.10.10.13291","article-title":"Kaposi's sarcoma associated herpesvirus-encoded viral FLICE inhibitory protein (vFLIP) K13 cooperates with Myc to promote lymphoma in mice","volume":"10","author":"Ahmad","year":"2010","journal-title":"Cancer Biol Ther"},{"issue":"34","key":"2019111717365866500_B69","doi-asserted-by":"crossref","first-page":"4979","DOI":"10.1038\/sj.onc.1210299","article-title":"Deregulation of c-Myc in primary effusion lymphoma by Kaposi's sarcoma herpesvirus latency-associated nuclear antigen","volume":"26","author":"Bubman","year":"2007","journal-title":"Oncogene"},{"issue":"4","key":"2019111717365866500_B70","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1182\/blood.V95.4.1406.004k26_1406_1412","article-title":"HHV-8 is associated with a plasmablastic variant of Castleman disease that is linked to HHV-8-positive plasmablastic lymphoma","volume":"95","author":"Dupin","year":"2000","journal-title":"Blood"},{"issue":"7","key":"2019111717365866500_B71","first-page":"486","article-title":"Castleman disease in the 21st century: an update on diagnosis, assessment, and therapy","volume":"8","author":"van Rhee","year":"2010","journal-title":"Clin Adv Hematol Oncol"},{"issue":"9","key":"2019111717365866500_B72","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1097\/PAS.0b013e31804d43d8","article-title":"HHV-8+, EBV+ multicentric plasmablastic microlymphoma in an HIV+ man: The spectrum of HHV-8+ lymphoproliferative disorders expands","volume":"31","author":"Seliem","year":"2007","journal-title":"Am J Surg Pathol"},{"issue":"6","key":"2019111717365866500_B73","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.semcancer.2009.07.004","article-title":"Burkitt's lymphoma: the Rosetta Stone deciphering Epstein-Barr virus biology","volume":"19","author":"Rowe","year":"2009","journal-title":"Semin Cancer Biol"},{"issue":"3","key":"2019111717365866500_B74","doi-asserted-by":"crossref","first-page":"e1000341","DOI":"10.1371\/journal.ppat.1000341","article-title":"An Epstein-Barr virus anti-apoptotic protein constitutively expressed in transformed cells and implicated in Burkitt lymphomagenesis: the Wp\/BHRF1 link","volume":"5","author":"Kelly","year":"2009","journal-title":"PLoS Pathog"},{"issue":"6","key":"2019111717365866500_B75","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1182\/blood-2010-05-285791","article-title":"Lymphomas differ in their dependence on Epstein-Barr virus","volume":"117","author":"Vereide","year":"2011","journal-title":"Blood"},{"issue":"2","key":"2019111717365866500_B76","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/leu.2008.281","article-title":"Translocations involving 8q24 in Burkitt lymphoma and other malignant lymphomas: a historical review of cytogenetics in the light of today's knowledge","volume":"23","author":"Boerma","year":"2009","journal-title":"Leukemia"},{"issue":"6","key":"2019111717365866500_B77","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1097\/PAS.0b013e3181db83af","article-title":"Altered subcellular localization of c-Myc protein identifies aggressive B-cell lymphomas harboring a c-MYC translocation","volume":"34","author":"Ruzinova","year":"2010","journal-title":"Am J Surg Pathol"},{"issue":"23","key":"2019111717365866500_B78","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1056\/NEJMoa055759","article-title":"Molecular diagnosis of Burkitt's lymphoma","volume":"354","author":"Dave","year":"2006","journal-title":"N Engl J Med"},{"issue":"23","key":"2019111717365866500_B79","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa055351","article-title":"A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling","volume":"354","author":"Hummel","year":"2006","journal-title":"N Engl J Med"},{"issue":"7","key":"2019111717365866500_B80","doi-asserted-by":"crossref","first-page":"935","DOI":"10.3324\/haematol.2008.005355","article-title":"Clinicopathological features of lymphoma\/leukemia patients carrying both BCL2 and MYC translocations","volume":"94","author":"Tomita","year":"2009","journal-title":"Haematologica"},{"issue":"3","key":"2019111717365866500_B81","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1097\/PAS.0b013e3181cd3aeb","article-title":"B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma","volume":"34","author":"Snuderl","year":"2010","journal-title":"Am J Surg Pathol"},{"issue":"11","key":"2019111717365866500_B82","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1182\/blood-2009-03-212191","article-title":"Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival","volume":"114","author":"Johnson","year":"2009","journal-title":"Blood"},{"issue":"8","key":"2019111717365866500_B83","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1182\/blood-2010-09-297879","article-title":"Double-hit B-cell lymphomas","volume":"117","author":"Aukema","year":"2011","journal-title":"Blood"},{"issue":"20","key":"2019111717365866500_B84","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1200\/JCO.2009.26.3947","article-title":"Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab","volume":"28","author":"Barrans","year":"2010","journal-title":"J Clin Oncol"},{"key":"2019111717365866500_B85","volume-title":"Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues","author":"Jaffe","year":"2001"},{"issue":"14","key":"2019111717365866500_B86","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1200\/JCO.2010.32.8385","article-title":"The gray zone between Burkitt's lymphoma and diffuse large B-cell lymphoma from a genetics perspective","volume":"29","author":"Salaverria","year":"2011","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019111717365866500_B87","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1200\/JCO.1996.14.3.955","article-title":"Anaplastic large-cell lymphoma: clinical and prognostic evaluation of 90 adult patients","volume":"14","author":"Zinzani","year":"1996","journal-title":"J Clin Oncol"},{"key":"2019111717365866500_B88","article-title":"Gray zone lymphoma: chromosomal aberrations with immunophenotypic and clinical correlations [published online ahead of print August 5, 2011]","author":"Eberle","journal-title":"Mod Pathol"},{"issue":"4","key":"2019111717365866500_B89","doi-asserted-by":"crossref","first-page":"558","DOI":"10.3324\/haematol.2010.033167","article-title":"Methylation profiling of mediastinal gray zone lymphoma reveals a distinctive signature with elements shared by classical Hodgkin's lymphoma and primary mediastinal large B-cell lymphoma","volume":"96","author":"Eberle","year":"2011","journal-title":"Haematologica"},{"key":"2019111717365866500_B90","first-page":"134","article-title":"Untreated primary mediastinal B-cell (PMBL) and mediastinal grey zone (MGZL) lymphomas: comparison of biological features and clinical outcome following DA-EPOCH-R without radiation","volume":"22","author":"Dunleavy","year":"2011","journal-title":"Ann Oncol"},{"issue":"3","key":"2019111717365866500_B91","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/00000478-200103000-00003","article-title":"Pathologic and clinical features of 77 Hodgkin's lymphoma patients treated in a lymphoma protocol (LNH87): a GELA study","volume":"25","author":"Cazals-Hatem","year":"2001","journal-title":"Am J Surg Pathol"},{"issue":"24","key":"2019111717365866500_B92","doi-asserted-by":"crossref","first-page":"6069","DOI":"10.1182\/blood-2009-01-199679","article-title":"Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma","volume":"113","author":"Dunleavy","year":"2009","journal-title":"Blood"},{"issue":"1","key":"2019111717365866500_B93","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/nchembio.502","article-title":"Drug discovery: New Btk inhibitor holds promise","volume":"7","author":"Hendriks","year":"2011","journal-title":"Nat Chem Biol"},{"issue":"8","key":"2019111717365866500_B94","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.1182\/blood-2008-02-137372","article-title":"Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP","volume":"112","author":"Rimsza","year":"2008","journal-title":"Blood"},{"issue":"5","key":"2019111717365866500_B95","doi-asserted-by":"crossref","first-page":"680","DOI":"10.2353\/jmoldx.2010.090164","article-title":"A novel method of amplification of FFPET-derived RNA enables accurate disease classification with microarrays","volume":"12","author":"Williams","year":"2010","journal-title":"J Mol Diagn"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2011\/1\/506\/1494274\/bep00111000506.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2011\/1\/506\/1494274\/bep00111000506.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,19]],"date-time":"2021-12-19T05:01:32Z","timestamp":1639890092000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2011\/1\/506\/96964\/Aggressive-BCell-Lymphomas-A-Review-of-New-and-Old"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12,10]]},"references-count":95,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,12,10]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2011.1.506","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,12,10]]}}}